Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00038779 · ClinicalTrials.gov registry record · NA
Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00038779: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00038779 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00038779, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.
Interventions
- PROCEDURE Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 1996-08-14 |
| Est. Completion | 2004-09-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00038779
The ClinicalTrials.gov registry entry for NCT00038779 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation is the first listed.
NCT00038779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00038779 about?
NCT00038779 is a clinical study titled "Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States". The purpose of this study is to assess early treatment failure within 100 days and to assess the effect of this regimen on engraftment, GVHD, immune recovery, relapse of malignancy and survival.
What is the current status of trial NCT00038779?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 1996-08-14. Estimated completion is 2004-09-20.
What interventions are being tested in trial NCT00038779?
The interventions under investigation include: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00038779?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.